MindMed

Mind Medicine/MindMed, Inc.
Company type	Public
Traded as	Nasdaq: MNMD;
ISIN	CA60255C8850
Industry	Biotechnology; Mental health
Founded	May 2019, in Toronto, Canada
Founder	Jamon "JR" Rahn ; Stephen Hurst ; Scott Freeman; Leonard Latchman
Headquarters	New York, U.S.
Area served	Worldwide
Key people	Robert Barrow (CEO); Daniel R Karlin, MD, MA (CMO);
Services	Drug development; Psychedelic research; Psychedelic assisted therapy;
Number of employees	57
Subsidiaries	MindMed Discover (Basel, Switzerland); MindMed Pty Ltd. (Perth, Western Australia)
Website	mindmed.co

Mind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.^[2]

^ Yakowicz, Will. "Psychedelics Company MindMed Trips In Nasdaq Debut". Forbes. Retrieved 2021-05-31.
^ "Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Emerging as a Leader in Brain Health Treatments". BeyondSPX. ISSN 0099-9660.

[Forbes_public-1] Yakowicz, Will. "Psychedelics Company MindMed Trips In Nasdaq Debut". Forbes. Retrieved 2021-05-31.

[WSJ-2] "Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Emerging as a Leader in Brain Health Treatments". BeyondSPX. ISSN 0099-9660.

[1]

[2]